Adam Baumgarten, MD
Urology · Birmingham, ALNPI 1538587076
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $179,791 of the $271,375 with a category attached, or 66.3%. Coloplast accounts for 76.9% of it on its own, with 16 other manufacturers making up the rest. 2025 is the largest year on record at $98,993, more than ten times the $619 reported in 2019. Among urology clinicians in AL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 627 payments — averaging $432.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Coloplast$209K
- Boston Scientific$55K
- Laborie Medical Technologies Corp.$5K
- Axonics, Inc.$1K
- Procept Biorobotics Corporation$408
- Bluewind Medical$278
- plus $1K from 11 others
Across 8 payments — averaging $9405.58 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Boston Scientific$46K
- Bluewind Medical$30K
What the payments were for
- Consulting fees$179,79166%
- Speaking & faculty fees$45,73017%
- Travel & lodging$19,1467%
- Food & beverage$23,3409%
- Education$3,3681%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Coloplast | 343 | $208,675 |
| Boston Scientific | 218 | $54,761 |
| Laborie Medical Technologies Corp. | 4 | $4,910 |
| Axonics, Inc. | 27 | $1,258 |
| Procept Biorobotics Corporation | 5 | $408 |
| Bluewind Medical | 8 | $278 |
| Endo Pharmaceuticals Inc. | 7 | $248 |
| Rigicon,inc. | 2 | $194 |
| Endo USA, Inc. | 3 | $164 |
| Olympus America Inc. | 1 | $136 |
| Cook Medical LLC | 1 | $119 |
| Medtronic | 2 | $96 |
| Cycle Pharmaceuticals Inc | 2 | $40 |
| Calyxo, Inc. | 1 | $26 |
| Civco Medical Instruments | 1 | $23 |
| Ambu Inc. | 1 | $21 |
| Sumitomo Pharma America, Inc. | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TITAN$202,298
- AdVance XP$17,954
- AMS 800 Artificial Urinary Sphincter$12,744
- AMS 700 CXR RTE KIT$4,877
- GENERAL MALE SUI$4,455
- Axonics$3,655
- AMS 700$2,711
- GENERAL - THERAPIES$1,800
- Optilume BPH Drug Coated Balloon Catheter$1,200
- GENERAL ERECTILE DYSFUNCTION$610
- ALTIS$316
- REZUM$258
- XIAFLEX$238
- GENERAL KIDNEY STONE DISEASE$145
- URETERO-RENO VIDEOSCOPE$136
- UroPass$136
- AQUABEAM SYSTEM$135
- Bulkamid$121
- Zenith Spiral-Z$119
- AquaBeam Robotic System$117
How this compares
$271,375 in reported general payments places this provider in the 95th percentile of 179 urology providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 104 | $50,961 |
| Testosterone | 36 | $10,268 |
| GemtesaVibegron | 16 | $7,372 |
| Testosterone Cypionate | 74 | $2,995 |
| Tamsulosin Hcl | 45 | $956 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 25 | $490 |
| Oxybutynin Chloride ErOxybutynin Chloride | 32 | $486 |
| Oxybutynin Chloride | 12 | $156 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 11 | $105 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 23 | $57 |
| Ciprofloxacin Hcl | 12 | $50 |
| Oxycodone Hcl | 34 | $34 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Sumitomo Pharma America, Inc.Gemtesa | $19 | $7,37216 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 179 urology providers in Alabama.
Other urology in Birmingham
- Thomas ChiBirmingham$463K
- Joel FunkBirmingham$347K
- Kyle WoodBirmingham$91K
- Jeffrey NixBirmingham$54K
- Tracey WilsonBirmingham$38K
- Charles PeytonBirmingham$27K
- Kazumi TaguchiBirmingham$19K
- Andrew FangBirmingham$5K
- Kyle GennaroBirmingham$5K
- Brian ChristineHomewood$215K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.